Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
102 hedge funds and large institutions have $268M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 7 closing their positions.
177% more call options, than puts
Call options by funds: $7.52M | Put options by funds: $2.71M
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
50% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 24
10% more funds holding
Funds holding: 93 → 102 (+9)
2% less capital invested
Capital invested by funds: $272M → $268M (-$4.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.3M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$3.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.62M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$4.63M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.12M |
| 3 |
Jennison Associates
New York
|
-$3.79M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.34M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
101
BlackRock Group
London,
United Kingdom
| $3K | -$24K | -560 | -88% |
|
102
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $374 | -$13.1K | -307 | -3% |
|
|
SIM
103
SSI Investment Management
Los Angeles,
California
| – | -$365K | -8,696 | Closed |
|
104
D.E. Shaw & Co
New York
| – | -$113K | -2,683 | Closed |
|
105
Two Sigma Investments
New York
| – | -$101K | -2,405 | Closed |
|
|
AB
106
Amalgamated Bank
New York
| – | -$54K | -1,275 | Closed |
|
107
Invesco
Atlanta,
Georgia
| – | -$32K | -763 | Closed |
|
108
Citadel Advisors
Miami,
Florida
| – | -$31.2K | -729 | Closed |
|
|
PAM
109
Panagora Asset Management
Boston,
Massachusetts
| – | -$20K | -486 | Closed |
|
MACK Hedge Fund Activity: Q1 2014 in Review
102 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2014, worth a combined $268M — down 1.6% from $272M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MACK positions and 7 closed out — a net gain of 10 holders — while 36 added to existing stakes and 24 trimmed.
The largest buyer was State Street, adding an estimated $17.3M. The largest seller was Magnetar Financial, cutting an estimated $4.63M.
- 102 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2014, up from 93 in Q4 2013.
- Funds reported $268M of Merrimack Pharmaceuticals, Inc. stock for Q1 2014, down 1.6% quarter-over-quarter.
- 17 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2014 and 7 closed out, a net change of +10 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2014 was State Street, an estimated $17.3M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2014 was Magnetar Financial, an estimated $4.63M sold.
Based on aggregated 13F filings for Q1 2014.